Logo

Thermo Fisher Provides Notice on Convertible Debentures

Jul 07, 2009

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today provided notice to holders of certain bonds have the right to convert the debentures.

The firm said that holders of Apogent Technologies' Floating Rate Convertible Senior Debentures due 2033 may convert the debentures because Thermo Fisher's stock has traded above the minimum price specified in the indenture over the applicable measurement period.

Thermo Fisher assumed the debentures as part of its acquisition of Apogent in 2004.

The firm said that the debentures continue to be convertible until Sep. 26, 2009, and may be convertible thereafter, depending on whether or not one of the conversion conditions specified in the indenture is satisfied during future measurement periods. Thermo Fisher said that if it receives conversion requests, it has the right to decide whether to pay bond holders in cash or a combination of cash and shares of its common stock.

Filed under

Thermo Fisher Scientific
Breaking News
The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.